Very early researchEnded earlyNCT00253461What this trial is testing11C Topotecan PET ImagingWho this might be right forLung CancerMetastatic CancerOvarian Cancer+1 more Case Comprehensive Cancer Center 7
Large-scale testing (Phase 3)Study completedNCT03940196What this trial is testingEffect of Tumor Treating Fields (TTFields, 200 kHz) Concomitant With Weekly Paclitaxel for the Treatment of Recurrent Ovarian Cancer (ENGOT-ov50 / GOG-3029 / INNOVATE-3)Who this might be right forOvarian Cancer NovoCure Ltd. 540
Not applicableTemporarily pausedNCT03987555What this trial is testingPaclitaxel Therapeutic Drug Monitoring in Cancer PatientsWho this might be right forSolid Tumor, AdultMetastatic Nonsmall Cell Lung CancerAnatomic Stage IV Breast Cancer AJCC v8+25 more Wake Forest University Health Sciences 55
Early research (Phase 1)Looking for participantsNCT06515613What this trial is testingCTIM-76 in Patients With Recurring Ovarian Cancer and Other Advanced Solid TumorsWho this might be right forPlatinum-resistant Ovarian CancerTesticular CancerEndometrial Cancer Context Therapeutics Inc. 156
Testing effectiveness (Phase 2)Study completedNCT01611558What this trial is testingPhase II Study of Ipilimumab Monotherapy in Recurrent Platinum-sensitive Ovarian CancerWho this might be right forPlatinum-sensitive Ovarian Cancer, Second-line, Third-line, or Fourth-line Bristol-Myers Squibb 40
Early research (Phase 1)Study completedNCT00005858What this trial is testingLMB-9 Immunotoxin in Treating Patients With Advanced Colon, Breast, Non-small Cell Lung, Bladder, Pancreatic, or Ovarian CancerWho this might be right forBladder CancerBreast CancerColorectal Cancer+3 more University of Maryland, Baltimore 25
Testing effectiveness (Phase 2)Active Not RecruitingNCT04781088What this trial is testingLenvatinib, Pembrolizumab, and Paclitaxel for Treatment of Recurrent Endometrial, Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal CancerWho this might be right forPlatinum-Resistant Fallopian Tube CarcinomaPlatinum-Resistant Ovarian CarcinomaPlatinum-Resistant Primary Peritoneal Carcinoma+4 more Floor Backes, MD 38
Early research (Phase 1)Study completedNCT00058435What this trial is testingMonoclonal Antibody Vaccine Therapy in Treating Patients With Ovarian Epithelial, Fallopian Tube, or Peritoneal CancerWho this might be right forFallopian Tube CancerOvarian CancerPrimary Peritoneal Cavity Cancer Memorial Sloan Kettering Cancer Center
Testing effectiveness (Phase 2)UnknownNCT03942068What this trial is testingApatinib With Albumin-bound Paclitaxel in Patients With Platinum-resistant Recurrent Ovarian CancerWho this might be right forOvarian Cancer Henan Cancer Hospital 35
Testing effectiveness (Phase 2)Looking for participantsNCT07714668What this trial is testingA Clinical Study of SYS6041 Combination Therapy for Recurrent Ovarian CancerWho this might be right forOvarian CancerRecurrent Ovarian Cancer CSPC Megalith Biopharmaceutical Co.,Ltd. 171
Early research (Phase 1)Active Not RecruitingNCT04670068What this trial is testingPhase I Study of Autologous CAR T-Cells Targeting the B7-H3 Antigen in Recurrent Epithelial OvarianWho this might be right forEpithelial Ovarian Cancer UNC Lineberger Comprehensive Cancer Center 4
Early research (Phase 1)Study completedNCT03586661What this trial is testingNiraparib and Copanlisib in Treating Patients With Recurrent Endometrial, Ovarian, Primary Peritoneal, or Fallopian Tube CancerWho this might be right forDeleterious BRCA1 Gene MutationDeleterious BRCA2 Gene MutationEndometrial Adenocarcinoma+8 more M.D. Anderson Cancer Center 31
Early research (Phase 1)Study completedNCT00006391What this trial is testingOxaliplatin and Topotecan in Treating Patients With Previously Treated Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube CancerWho this might be right forFallopian Tube CancerOvarian CancerPeritoneal Cavity Cancer NYU Langone Health
Testing effectiveness (Phase 2)Active Not RecruitingNCT06028932What this trial is testingSacituzumab Govitecan (IMMU-132) in Platinum-resistant Ovarian Cancer PatientsWho this might be right forOvarian Carcinoma Yale University 20
Large-scale testing (Phase 3)Looking for participantsNCT05255471What this trial is testingMITO 35B: Olaparib Beyond Progression Compared to Platinum Chemotherapy After Secondary Cytoreductive Surgery in Recurrent Ovarian Cancer Patients.Who this might be right forOvarian Cancer National Cancer Institute, Naples 200
Testing effectiveness (Phase 2)UnknownNCT04734665What this trial is testingNiraparib and Bevacizumab Maintenance Therapy in Platinum-sensitive Recurrent Ovarian Cancer Patients Previously Treated With a PARP InhibitorWho this might be right forPlatinum-sensitive Recurrent Ovarian Cancer Patients Previously Treated With a PARP Inhibitor Yonsei University 44
Early research (Phase 1)Study completedNCT01264432What this trial is testingVeliparib and Radiation Therapy in Treating Patients With Advanced Solid Malignancies With Peritoneal Carcinomatosis, Epithelial Ovarian, Fallopian, or Primary Peritoneal CancerWho this might be right forAdult Solid NeoplasmPeritoneal CarcinomatosisRecurrent Fallopian Tube Carcinoma+2 more National Cancer Institute (NCI) 34
Early research (Phase 1)Study completedNCT01322802What this trial is testingVaccine Therapy in Treating Patients With Stage III-IV or Recurrent Ovarian CancerWho this might be right forStage III Ovarian Epithelial CancerStage III Ovarian Germ Cell TumorStage IV Ovarian Epithelial Cancer+1 more University of Washington 25
Testing effectiveness (Phase 2)Ended earlyNCT00023907What this trial is testingPaclitaxel in Treating Patients With Ovarian Epithelial Cancer or Primary Peritoneal CancerWho this might be right forOvarian CancerPrimary Peritoneal Cavity Cancer Gynecologic Oncology Group
Testing effectiveness (Phase 2)Ended earlyNCT06865677What this trial is testingSacituzumab Govitecan for Relapsed Ovarian, Endometrial, and Cervical CarcinomasWho this might be right forRecurrent Platinum Resistant Epithelial Ovarian CarcinomaRecurrent Epithelial Endometrial CarcinomaRecurrent Epithelial Cervical Carcinoma National Cancer Institute (NCI) 2